Alpha Teknova, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $467.6M
- Price
- $8.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.46%
- Volume
- 267.7K
About
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Quick stats
Shares outstanding53.7M
Computed float8.5M
Float / shares15.9%
Cash runway (months)34.2
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001850902
Websitehttps://www.teknova.com
AI Summary
AI-generated1/19
minorbullishregulatory
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
Teknova and Pluristyx announced Pluristyx is completing a Type II Drug Master File for the PluriFreeze cryopreservation system for FDA submission; Teknova is the exclusive US and Canada manufacturer and distributor of the product line.
The DMF lets drug developers request a letter of authorization and cross-reference PluriFreeze in IND and BLA applications, streamlining CMC documentation as cell therapy programs advance toward the clinic.
The filing builds on the March 2025 collaboration and supports Teknova's strategy of moving reagent customers from research-use into GMP and commercial manufacturing at its Hollister, California facilities.